CANCERKINE project receives funding from the Ministry of Science and Innovation
The project named CANCERKINE and title ‘Preclinical development of monoclonal antibodies against IL13Ra2 for [...]
PROALT selected by the European Innovation Council to pitch at the EIC Investor Day with CUF
PROALT has been selected by the European Innovation Council (EIC) to pitch its innovative [...]
PROALT participates in Anglonordic Life Science Conference 2022
Anti-CDH17 and anti-IL13Ra2 monoclonal antibodies developed by PROALT togheter with the Spanish Research Council [...]
ProAlt’s COO participates in a discussion panel at Asebio Investor Day 2022
PROTEIN ALTERNTIVES Chief Operating Officer Mr Juan Ignacio Imbaud has participated today in the second [...]
PROALT awarded with the Prize for the BEST BIOTECHNOLOGICAL STARTUP
Protein Alternatives SL (PROALT) received the Prize as the BEST BIOTECHNOLOGICAL STARTUP in the [...]
ProAlt will attended the 10th International Biotechnology Trade Show BioSpain 2021
September 14th, 2021 ProAlt will be present at BioSpain 2021 from the 29th September [...]
